This is the first report of adalimumab-associated pulmonary cryptococcosis. A 56-year-old female with rheumatoid arthritis without a history of pulmonary disease was simultaneously administered adalimumab (40 mg/2 wks), methotrexate (4 mg/wk), and isoniazid (200 mg/day). Five months later, chest radiography revealed a small spiculated pulmonary nodule, and the laboratory test results, including levels of tumor markers and plasma β-D-glucan, were within normal ranges. Since the lesion continued to grow, even after discontinuing adalimumab, it was surgically resected. Grocott staining of the tissue sample revealed black-brown fungi, identified as Cryptococcus neoformans in culture. The patient now remains well, without adalimumab therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5761/atcs.cr.10.01561 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Do histopathological features correlate with systemic manifestations in dermatomyositis? Analysis of 42 skin biopsy specimens from 22 patients.
J Cutan Pathol
May 2022
Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
Article Synopsis
- The study investigates if specific histopathological features in skin biopsies can predict systemic associations in patients with dermatomyositis (DM).
- It finds that while vacuolar interface dermatitis was the most common feature, no specific biopsy result reliably indicated other serious conditions like myopathy or interstitial lung disease.
- However, a correlation was noted between dense lichenoid infiltrate and severe itching, and MDA-5 antibody positive patients showed a higher likelihood of vasculopathy.
Hepatitis and pneumonitis during adalimumab therapy in Crohn disease: mind the histoplasmosis!
Arq Gastroenterol
November 2014
Divisão de Gastroenterologia, Departamento de Medicina, Centro de Doenças Inflamatórias Intestinais, Hospital da Universidade Federal de Juiz de Fora>, Juiz de Fora, MG, Brasil.
Context: Tumor necrosis factor-alpha (TNF-α) inhibitor therapy plays a pivotal role in the management of moderate to severe inflammatory bowel disease. Because of the role of TNF-α in the host defenses, anti-TNF therapy has been associated with an increase the risks of granulomatous infections.
Objective: To report the first case of adalimumab-associated invasive histoplasmosis presenting as an acute hepatitis-like syndrome and febrile pneumonitis in a patient with Crohn's disease.
Adalimumab-associated pulmonary cryptococcosis.
Ann Thorac Cardiovasc Surg
January 2012
Department of Thoracic Surgery, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan.
This is the first report of adalimumab-associated pulmonary cryptococcosis. A 56-year-old female with rheumatoid arthritis without a history of pulmonary disease was simultaneously administered adalimumab (40 mg/2 wks), methotrexate (4 mg/wk), and isoniazid (200 mg/day). Five months later, chest radiography revealed a small spiculated pulmonary nodule, and the laboratory test results, including levels of tumor markers and plasma β-D-glucan, were within normal ranges.
View Article and Find Full Text PDFA case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis.
Mod Rheumatol
October 2010
Department of Rheumatology, Ome Municipal General Hospital, 4-16-5 Higashi-Ome, Ome, Tokyo 198-0042, Japan.
A 64-year-old woman with rheumatoid arthritis (RA) began to complain of recurrent non-productive cough 5 months after starting adalimumab. The chest radiograph and high-resolution computed tomographic findings revealed diffuse ground-glass attenuation. Her clinical course suggested that interstitial pneumonia (IP) may have been induced by adalimumab, and she was successfully treated with a medium dose of corticosteroid.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!